重組人干擾素α2b陰道泡騰片治療宮頸高危型hpv感染的療效分析范本(存儲(chǔ)版)
【正文】 陽性2例，其它類型HPV感染48例。療程結(jié)束后，統(tǒng)計(jì)2組HPV轉(zhuǎn)陰率，觀察實(shí)驗(yàn)組用藥不良反應(yīng)。 [關(guān)鍵詞] 高危HPV感染；宮頸粘膜慢性炎；宮頸上皮內(nèi)瘤變1級(jí)；重組人干擾素α2b 陰道泡騰片 [中圖分類號(hào)] R711 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 16740742（2017）11（c）014003 [Abstract] Objective This paper tries to investigate the clinical effect of rebinant human interferon α2b vaginal effervescence tablet in the treatment of high risk human papillomavirus （HPV） infection. Methods 115 cases of cervical highrisk HPV infection patients from June 2016 to April 2017 were convenient selected and divided into the experimental group （rebinant human interferon α2b vaginal effervescent tablets， 58 cases） and the control group （regular followup， 57 cases）， after the treatment， the HPV negative rate and adverse reaction of the two groups were pared. Results The total negative rate of HPV in the experimental group was %， significantly higher than that in the control group of %， the difference was statistically significant（P）， the patients had no obvious disfort， and the adverse reaction rate was %. Conclusion Rebinant hu
環(huán)評(píng)公示相關(guān)推薦
鄂ICP備17016276號(hào)-1